DiagnosTear Announces Interim Clinical Study Results Demonstrating Excellent Correlation Between TeaRx(TM) Red Eye and Quantitative ELISA Testing

About this update from Diagnostear Technologies, Inc.

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, is pleased to announce positive interim analytical results from its ongoing clinical study with AlyaTec for TeaRx™ Red Eye, further to the Company's press releases dated December 2, 2025 and February 26, 2026. Interim results were obtained and analyzed from 30 tear samples originating from the first 10 subjects tested before and after ocular provocation with feline allergen. Each tear sample was tested using both the TeaRx™ Red Eye product developed by the Company and a quantitative reference Enzyme Immunoassay (ELISA) for human Immunoglobulin E (IgE). The results indicated excellent concordance between the two methods, with a correlation coefficient (R2) greater than 0.95. TeaRx™ Red Eye is being developed as a rapid, multi-biomarker diagnostic test designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis at the point of care. The Company believes that the ability to rapidly identify active ocular allergy through tear-based total IgE testing could meaningfully improve clinical decision-making and support more precise management of red eye conditions. Dr. Shimon Gross, CEO of DiagnosTear, commented: "These interim results represent a significant advancement for our Red Eye program. Demonstrating excellent correlation between TeaRx™ Red Eye and a quantitative ELISA reference method provides further support for the analytical performance of our platform and strengthens the scientific foundation for our regulatory strategy." Dr. Gross added: "We are encouraged by the high level of concordance observed in the first 30 tear samples tested. These results bring us closer to completing our analytical validation work and preparing for external, independent clinical trials designed to support our planned FDA 510(k) and CLIA waiver dual submission pathway." The Company expects to continue advancing the study with AlyaTec and will provide further updates as additional results become available. About DiagnosTear Technologies Inc. DiagnosTear Technologies Inc. is a global leader in rapid, point-of-care diagnostics for ocular diseases. The Company develops multi-parametric tests that provide fast, clinically actionable insi...

View stock analysis, news, and events for Diagnostear Technologies, Inc.